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Abstract DMBT1 (deleted in malignant brain tumor 1), which
encodes a large scavenger receptor cysteine rich (SRCR) B
protein, has been proposed to be a tumor suppressor gene, due
to the high frequency of its homozygous deletion and the lack of
expression in a variety of cancers. However, studies on its phys-
iological functions and its relationship with tumorigenesis are
still at an initial stage. Two mucosal defense-related molecules,
gp-340 and salivary agglutinin, have been identi¢ed to be alter-
natively spliced products of DMBT1, which suggests that
DMBT1 is a pattern recognition receptor in innate immunity.
Meanwhile, results from immunohistochemical staining and
studies at the cellular level, began to associate DMBT1 with
a proliferation to di¡erentiation switching process in gastroin-
testinal epithelial cells. Together with its up-regulation in in-
£ammation, these ¢ndings suggest that DMBT1 might be a
local regulator of homeostasis, possibly through linking mucosal
in£ammation to the modulation of epithelial regeneration, and
whose abnormality is a frequent cause of malignancy.
/ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Human DMBT1 (deleted in malignant brain tumor 1) was
cloned 5 years ago, from a homozygous deletion found in a
medulloblastoma cell line at 10q25.3-q26.1 [1], a chromosomal
region that frequently shows losses of heterozygosity (LOHs)
in a variety of tumors [2^4]. The prototype protein deducted
from the genomic sequence is composed of 13 highly homol-
ogous (87^100% identical) scavenger receptor cysteine rich
(SRCR) domains separated by SIDs (SRCR-interspersed do-
mains), which are followed by two CUB (C1r/C1s Uegf
Bmp1) domains £anking the 14th SRCR and then a ZP
(zona pellucida) domain toward the C-terminus [5]. A putative
exon 55 that encodes 19 hydrophobic amino acids compatible
with a transmembrane domain (TMD) has been identi¢ed at
the genomic level. Unlike DMBT1 homologs in mouse [6] and
rat [7], the TMD was not found at the cDNA level in human
[5]. In addition to the 14 putative sites for N-linked glycosyl-
ation found in this deduced amino acid sequence [8], a high
density of potential O-glycosylation sites was proposed within
the SIDs [9]. SRCR, CUB and ZP domains have all been
implicated in mediating protein^protein interactions [10^13].
The SRCR/CID boundaries generate multiple spliced form of
this molecule [5,14]. Two human proteins, gp-340 and salivary
agglutinin, both containing 14 SRCR domains, have been
shown to be encoded by the DMBT1 gene [8,15,16]. The
same gene is also believed to produce transcripts of di¡erent
sizes in rabbit, mouse and rat, namely, hensin, CRP-ductin,
and Ebnerine, respectively [17^19] (see their structure compar-
isons in these references and ref. [8]). Immunohistochemical
staining and reverse transcriptase-polymerase chain reaction
(RT-PCR) studies demonstrated a wide range of body loca-
tions for DMBT1, mostly of epithelial origin, with high levels
found in the respiratory system (i.e. trachea and lung) and the
alimentary system (particularly small intestine, also salivary
gland and stomach) [1,8,18], and moderate levels in brain
[18] and the reproductive system (i.e. testis and mammary
gland) [8]. The currently available data suggests two functions
for DMBT1, in mucosal defence and in epithelial di¡erentia-
tion [18]. We have reviewed the participation of DMBT1 in
these two areas. By reviewing recent data on the better-
studied gastric mucosa, we will illustrate how DMBT1 may
carry out its dual functions within the same tissue.
2. DMBT1 and tumorigenesis
Initial demonstration of a frequent loss or reduction of the
expression, and the deletion of the DMBT1 gene, possibly due
to its increasing susceptibility to genomic instability, led to the
assumption that it is a putative tumor suppressor for brain
[1,20], gastrointestinal [21] and lung [22] cancers. However,
recent work revealed further complexity between the abnor-
malities of DMBT1 and various cancers. Only infrequent and
small mutations of the gene were found in gliomas [23], sug-
gesting that DMBT1 polymorphisms are not likely primary
targets of 10q loss in gliomagenesis [24]. Analysis of LOHs
also showed DMBT1 unlikely to be a major inactivation tar-
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get in the development of melanomas [25]. A mixed picture
was presented for lung tumors, where both down-regulation
[22,26] and insigni¢cant reduction [27] of the DMBT1 level
were reported. More intriguingly, up-regulation of DMBT1
has been detected in certain glioblastoma multiforme
(GBM) [18], gastric adenocarcinoma (W. Kang et al., unpub-
lished observation) and tumor-£anking tissues in lung [28].
These variations and inductions of the DMBT1 expression
occur with high frequency, which strongly suggests an associ-
ation between this molecule and tumorigenesis at di¡erent
body locations. Clari¢cation, of such a complicated issue, re-
lies on conducting the functional studies both in vitro and in
vivo, to elucidate the exact physiological roles of DMBT1.
Several lines of evidences have been accumulated, which in-
dicate a direct involvement of DMBT1 in epithelial di¡eren-
tiation, whose abnormality is a frequent cause of cancer.
3. DMBT1 and epithelial development
DMBT1 was ¢rst related to epithelial di¡erentiation
through the functional studies of its orthologs, rabbit hensin
and mouse CRP-ductin. Hensin was found to be responsible
for the switch of the polarity and the induction of terminal
di¡erentiation, of intercalated epithelial cells in kidney [29,30],
possibly as an inside-out signaling molecule. By means of its
polymerization and deposition into the extracellular matrix
[31]. The three molecules share strong staining in the crypt
cells of the small intestine [6,18,32]. DMBT1 was also located
primarily along the neck region of normal human gastric mu-
cosa [33]. Both the crypt and isthmus regions are composed
predominantly of stem/progenitor cells, which actively prolif-
erate and di¡erentiate along the axis of epithelial migration.
Therefore such a characteristic localization of DMBT1 across
species, implicates its role in the physiological renewing pro-
cess of gastrointestinal epithelia. Immunohistochemical stain-
ing further revealed much stronger signals for DMBT1 in
fetus than in adult, as well as a distinct spatial distribution,
in gastrointestinal epithelium and epidermal cells [18], which
suggests a role DMBT1 might also play in the developmental
process at certain body locations. Tremendous progress has
been made in the investigation of DMBT1 at genomic and
transcript levels, which suggests a correlation between the
abnormalities of the gene and/or the expression of DMBT1,
and carcinogenesis in a variety of epithelia-related tumors.
Both the lack/reduction of transcripts and up-regulation of
the molecule have been detected for DMBT1 in lung and
gastrointestinal cancers [21,26,28]. These ¢ndings apparently
link the molecule to the process of epithelial development,
because neoplasia results directly from the disorders in the
growth of these cells. However, further investigation is re-
quired to clarify whether altered expressions of DMBT1 are
among the causes or the consequences of tumorigenesis. In a
recently conducted in vitro study, we demonstrated down-reg-
ulation/attenuation of DMBT1 in PMA induced di¡erentia-
tion of the gastric adenocarcinoma cell line AGS [33]. Further
analysis using this model system, led to the identi¢cation of
two intracellular signal molecules, protein kinase C and extra-
cellular signal-regulated kinase (ERK) MAPK, to be involved
in mediating both PMA regulation of the DMBT1 production
and its induction of AGS di¡erentiation. In a step-wise pro-
liferation to di¡erentiation switch constructed in AGS cells by
promoting or inhibiting the activation of ERK, the corre-
sponding changes of the expression of DMBT1 pinpoint its
synthesis to be turned on in di¡erentiation-committed cells
arrested in G1 phase, before the induction of terminal di¡er-
entiation-related phenotypes; and to be turned o¡ after these
phenotypes were steadily expressed (manuscript submitted).
This particular stage of expression is supported by the tightly
controlled spatial distribution of DMBT1 in gastrointestinal
stem/progenitor cells [18,33]. These results also ¢t well into a
recent report, which showed highly inducible expression of a
rat DMBT1 in transit-amplifying ductular (oval) cells (possi-
bly originating from endogenous stem cells) in regenerating
rat liver [19]. Both lines of evidence collected from di¡erent
assay systems indicate an important role for DMBT1 in cell
fate decision (i.e. as a critical determinant of di¡erentiation
paths leading to certain cell lineages [19]) at an early stage of
epithelial di¡erentiation.
4. DMBT1 and innate immunity
On the other hand, increasing data point the involvement of
DMBT1in the body’s ¢rst line defense. After the two innate
immune molecules in human, salivary agglutinin and gp-340,
were identi¢ed to be alternatively spliced forms of DMBT1
[8,15,16], a further study strikingly revealed that a synthetic
16-mer peptide from the SRCR domains of salivary agglutinin
bound a wide range of bacteria, including Streptococcus mu-
tans, Escherichia coli, Lactobacillus casei, Helicobacter pylori
and Prevotella intermedia, and mediated the agglutination of
S. mutans [9]. This is the ¢rst evidence showing that SRCR B
domains are responsible for the broad pathogenic recognition
of certain host molecules, and the potential protective e¡ect it
could mediate. In addition, salivary agglutinin forms hetero-
typic complexes with soluble immunoglobulin A (sIgA) in a
calcium dependent manner [34,35], which was suggested to be
essential for the interaction between agglutinin and a surface
protein antigen of S. mutans [35]. Gp-340 binds to collectins
surfactant protein (SP)-D and SP-A, two active components
in innate pulmonary defense [36]. RT-PCR and immunohis-
tochemical staining revealed an epithelia-associated distribu-
tion shared by SP-D and DMBT1 along the body mucosa or
ducts of glands [8,37,38], which allows them frequent contact
with pathogens that invade the inner surface of the body.
Epithelial cells have been regarded as ¢rst line defense com-
ponents to protect mucosal surface, by actively secreting sev-
eral pro-in£ammatory cytokines [33^35] and becoming anti-
gen-presenting cells [36,37] upon microbial challenges. Up-
regulation of DMBT1 was detected in the pulmonary cell
line A549 coinciding with the induction of cytokine IL-8
and IL-6 upon the in£ammatory challenge [33], as well as in
the epithelia of in£ammatory pulmonary tissues [28], which
suggests the increase of DMBT1 to be part of the epithelial
responses to local in£ammation. Moreover, DMBT1 and its
ligand SP-D are both synthesized by type II cells in lung,
indicating their possible collaboration in the mucosal immune
processes [33]. Gp-340 was also shown to stimulate random
migration (chemokinesis) of alveolar macrophages, suggesting
its direct regulation of tissue macrophages [39]. Taken togeth-
er, DBMT1 is acting as a typical pattern recognition receptor
in the body’s innate anti-microbial process, through interac-
tions with both invading pathogens and many other local
defense components. Using RT-PCR, transcripts of DMBT1
were detected throughout the immune system: in spleen and
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thymus, alveolar macrophages, T cell line Jurkat and B cell
line Raji [8,18]. Although the expression level might be very
low, and the epithelium cannot be ruled out as being to be the
major source of DMBT1 expression in lymphoid-organs, these
data may still suggest additional functions for DMBT1 in the
regulation of acquired immunity, as having been reported for
other proteins in SRCR B family [10,40].
5. DMBT1, a linkage between mucosal defense and epithelial
regeneration?
Based primarily on genomic mutation, expression and local-
ization studies, Mollenhauer and co-workers ¢rst proposed
dual functions for DMBT1 in mucosal defense and epithelial
di¡erentiation [18]. They drew a parallel between DMBT1 and
its homolog bovine gallbladder mucin (BGM) [41], as well as
another collectin-binding mucin Mac-2 [18,42], to explain the
multifunctioning potential of DMBT1. However, the primar-
ily known function of BGM is in the formation of crystal
through its binding to lipid components and calcium-binding
protein in bile [43,44]. Since particular attention in illustrating
the dual function of DMBT1 has been drawn in the lung and
gastrointestinal mucosa where the highest level of its expres-
sion was found in adults [1,8], two epithelial cell lines derived
from the lung and gastric mucosa were compared for their
responses to PMA treatment. This in vitro study allowed
the demonstration of in£ammation-related up-regulation of
DMBT1 in pulmonary epithelia, and di¡erentiation-related
down-regulation of this molecule in gastric epithelia [33].
Both ¢ndings are in line with the immunohistochemical anal-
ysis, which showed an increasing level of DMBT1 in in£am-
matory lung tissues [28], and predominant distribution of
DMBT1 in stem/progenitor cells rather than in terminally
di¡erentiated cells in gastrointestinal epithelia [6,18,33].
Therefore it appears that the two distinct functions of
DMBT1 might be body location-related, and epithelial di¡er-
entiation stage speci¢c [33]. In the gastrointestinal tract,
DMBT1 was found to be secreted from the apical membrane
of epithelia onto the mucosal surface, where binding of invad-
ing pathogens such as S. mutans and H. pylori [15], and host
defense components such as SP-D [45] and sIgA [35], could
take place. All these ligands are involved in local in£amma-
tion in gastric mucosa [46]. DMBT1 homologs have also been
identi¢ed as putative receptor for trefoil factors, the peptides
known to play a major role in the acute phase protection of
mucosa surface upon tissue injury [47]. Thus the protective
function of DMBT1 should be considered to cover a wider
area, rather than only monolayers of epithelia, as has been
proposed by Mollenhauer J et al. [41]. It seems likely that the
interactions of DMBT1 with many of these proteins, may be
mediated by one, or more, of the SRCR domains present in
DMBT1. Meanwhile, the CUB and ZP domains on its
C-terminus may interact with growth factors [48] or cell surface
molecules [13]. Thus, the local environmental signals could
apparently be integrated by DMBT1, and be transmitted to
the stem/progenitor cells through certain interactions it may
have with the surface of these cells. This might be one e⁄cient
means, by which the speed of epithelial regeneration could be
better modulated according to the speci¢c physiological and
pathological needs, through triggering immediate di¡erentia-
tion of the progenitor cells, and perhaps also stimulating their
proliferation (Fig. 1). The promotion of the regeneration ma-
chinery would be particularly important following mucosal
damage, such as in times of a severe local in£ammation in
spite of origins, or in the development of an ulcer. Rapid
regeneration of mucosal epithelia should be regarded as an
active part of the local defense mechanism, which would ef-
fectively limit the spread of an infection, and the tissue dam-
age resulting from exceeding in£ammatory reactions [47]. The
size of DMBT1 and the many protein^protein interaction in-
terphases it has, make this molecule one of the ideal linkages
between the mucosal defense and the regulation of epithelial
development. It might act in synergy, or in complement, with
other immune cytokines and growth factors, to maintain the
Fig. 1. Schematic representation of the epithelial di¡erentiation associated regulation of the expression of DMBT1 in gastrointestinal tract, and
of its potential roles in linking the mucosal in£ammation to the modulation of epithelia di¡erentiation, through its multiple bindings of patho-
gens and/or host defense components, growth factors and cell surface receptor(s).
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integrity and the functions of the body mucosa. It is therefore
not surprising that the abnormalities of DMBT1, a molecule
that is closely related to epithelial protection/regeneration, can
be found with high frequency in epithelial malignancy
[1,21,26].
6. Conclusion
Present research work on DMBT1 is focused primarily on
mutation, expression and localization analysis, which some-
times yield contradictory results, regarding the signi¢cance of
mutation/deletion and expression level of the DMBT1 gene in
carcinogenesis. These types of studies have laid the founda-
tions of the possible roles DMBT1 might play. However the
complexity in the functions of this molecule and its relation-
ship with di¡erent tumors, as well as its tremendous potential
in mediating protein^protein, protein^cell and cell^extracellu-
lar matrix interactions, require more direct functional studies
to be carried out in vitro and in vivo, which will shed light on
the exact roles of DMBT1 and the underlying molecular
mechanisms, and how these functions might change at distinct
body locations, and according to the combinations of envi-
ronmental signals under a whole variety of physiological and
pathological conditions. It is crucial to generate the knock out
model in mice, to which appropriate challenges could be ap-
plied to facilitate the in vivo comparison of the speci¢c roles
of DMBT1 in epithelial regeneration and local in£ammatory
reaction. Biochemical analysis is also needed, in identifying
and characterizing the potential carbohydrate and lipid, along
side protein ligands, for DMBT1. In combination with ap-
proaches at genomic, animal and tissue levels, cellular work
has proved to be a powerful tool, which should be further
explored to help reveal the molecular mechanisms. These in-
clude the regulation of the gene expression, identi¢cation of
possible cell surface receptors and intracellular signal path-
ways, by which DMBT1 in£uences particular cellular events.
Our understanding of this multifunctional molecule and fu-
ture perspective of treating certain types of cancer/infection
would be greatly enhanced through these e¡orts.
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